Investigating how cell-free hemoglobin affects lung injury during sepsis
Cell-free hemoglobin-oxidized LDL-LOX-1 axis and microvascular hyperpermeability during sepsis
This study is looking at how a substance called cell-free hemoglobin can harm the lungs in people with sepsis, which might help us find new ways to treat lung problems like ARDS.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Alabama NIH-funded |
| Lab location | 1 site (Mobile, United States) |
| Project ID | NIH-11127820 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms by which cell-free hemoglobin contributes to lung injury in patients with sepsis. It examines how this hemoglobin interacts with low-density lipoprotein to disrupt the barrier of microvascular endothelial cells, leading to increased permeability and acute respiratory distress syndrome (ARDS). By analyzing patient samples, the study aims to uncover the cellular and molecular pathways involved in this process, potentially identifying new targets for treatment. The approach combines clinical data with laboratory analysis to explore these interactions in depth.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with sepsis who are at risk of developing acute respiratory distress syndrome.
Not a fit: Patients who do not have sepsis or are not at risk for ARDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new prevention or treatment strategies for ARDS in sepsis patients.
How similar studies have performed: While the specific mechanisms being investigated are novel, previous research has shown that targeting similar pathways can lead to significant advancements in treating sepsis-related complications.
Where this research is happening
Mobile, United States
- University of South Alabama — Mobile, United States (Active)
Researchers
- Principal investigator: Meegan, Jamie E — University of South Alabama
- Study coordinator: Meegan, Jamie E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.